Amylin Pharmaceuticals Inc. on Sunday presented data from Phase II studies indicating that its AC137 amylin analog, tripro-amylin, can improve post-meal glucose control in patients with Type I (juvenile onset) diabetes.

The company also said the studies produced an unexpected result in a second area of interest, showing that AC137 didn't measurably alter hypoglycemia (low blood glucose) induced by an insulin overdose challenge, compared to placebo.